AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1642936 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac trometamol 10 mg administered 4‐hourly by intermittent i.m. injection or by continuous i.m. infusion
Number of subjects: 67
Study 1642936 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 67
Study 1642936 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac trometamol
Number of subjects: 67
Study 6829920 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (0.5% bupivacaine with epinephrine intraoperatively; 0.25% bupivacaine with epinephrine every 3 hours postoperatively)
Number of subjects: 60
Study 6829920 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (controlled ventilation with N2O‐O2, intravenous fentanyl and pancuronium bromide; narcotic analgesics intramuscularly on demand postoperatively)
Number of subjects: 60
Study 6829920 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 60
Study 6829920 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study 29676480 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication compliance and insight into schizophrenia
Number of subjects: 173
Study 29676480 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert witness explanation regarding medication compliance and insight
Number of subjects: 173
Study 27724965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (7-10 mmHg)
Number of subjects: 280
Study 27724965 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12-16 mmHg)
Number of subjects: 280
Study 24720702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir for 8 weeks
Number of subjects: 647
Study 24720702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir plus ribavirin for 8 weeks
Number of subjects: 647
Study 24720702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir for 12 weeks
Number of subjects: 647
Study 23771784 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin algorithm
Number of subjects: 130
Study 19201496 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg daily)
Number of subjects: 103
Study 19201496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 18036719 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5mg daily
Number of subjects: 8224
Study 18036719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8224
Study 16650232 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole single dose (400 mg)
Number of subjects: 150
Study 16650232 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg for 3 days)
Number of subjects: 150
Study 16650232 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% permethrin
Number of subjects: 150
Study 16650232 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% permethrin + albendazole single dose (400 mg)
Number of subjects: 150
Study 16650232 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% permethrin + albendazole (400 mg for 3 days)
Number of subjects: 150
Study 12880714 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 21
Study 12880714 — intervention group
Group type: COMPARATOR
Intervention: Males
Number of subjects: 21
Study 10961748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP) solution
Number of subjects: 300
Study 10961748 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol lavage
Number of subjects: 300
Study 10961748 — intervention group
Group type: COMPARATOR
Intervention: Senna compound
Number of subjects: 300
Study 9124864 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of pefloxacin twice daily for 5 days (group A)
Number of subjects: 46
Study 9124864 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of pefloxacin twice daily for 7 days (group B)
Number of subjects: 46
Study 1304992 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 40
Study 1304992 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40
Study 4025304 — intervention group
Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire
Number of subjects: 82
Study 4025304 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour recall
Number of subjects: 82
Study 4025304 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day food record
Number of subjects: 82
Study 4025304 — intervention group
Group type: COMPARATOR
Intervention: Food frequency questionnaire and three-day food record
Number of subjects: 82
Study 31718738 — intervention group
Group type: EXPERIMENTAL
Intervention: After Deployment, Adaptive Parenting Tools program (ADAPT), a 14-session group-based parenting intervention
Number of subjects: 181
Study 31718738 — intervention group
Group type: EXPERIMENTAL
Intervention: After Deployment, Adaptive Parenting Tools program (ADAPT)
Number of subjects: 181
Study 31718738 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 181
Study 29237339 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-and-music-based therapy (R-MT), n=37
Number of subjects: 106
Study 29237339 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse-riding therapy (H-RT), n=37
Number of subjects: 106
Study 29237339 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control group), n=32
Number of subjects: 106
Study 29237339 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-and-music-based therapy (R-MT) and Horse-riding therapy (H-RT)
Number of subjects: 106
Study 26972606 — intervention group
Group type: EXPERIMENTAL
Intervention: arginine+exercise (A‐E)
Number of subjects: 16
Study 26972606 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise+placebo (EXE)
Number of subjects: 16
Study 26972606 — intervention group
Group type: COMPARATOR
Intervention: arginine (ARG)
Number of subjects: 16
Study 26972606 — intervention group
Group type: COMPARATOR
Intervention: control (CON)
Number of subjects: 16
Study 24693891 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmune globulin
Number of subjects: 124
Study 24693891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 22784835 — intervention group
Group type: EXPERIMENTAL
Intervention: 52 mg hydrated implant
Number of subjects: 45
Study 22784835 — intervention group
Group type: EXPERIMENTAL
Intervention: 84 mg hydrated implant
Number of subjects: 45
Study 22784835 — intervention group
Group type: COMPARATOR
Intervention: 84 mg nonhydrated implant
Number of subjects: 45
Study 21167080 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine treatment with sarpogrelate (300 mg/day)
Number of subjects: 268
Study 21167080 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment without sarpogrelate
Number of subjects: 268
Study 17435520 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal Refractive Therapy (CRTH) lens (Dk = 100)
Number of subjects: 20
Study 17435520 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 20
Study 15616299 — intervention group
Group type: COMPARATOR
Intervention: Tigecycline single-dose (12.5 to 300 mg)
Number of subjects: 0
Study 15616299 — intervention group
Group type: COMPARATOR
Intervention: Tigecycline multiple-dose (25 to 100 mg every 12 h)
Number of subjects: 0
Study 15616299 — intervention group
Group type: COMPARATOR
Intervention: Tigecycline variable volume and infusion rate (100 mg loading dose, followed by 50 mg every 12 h for 5 days)
Number of subjects: 0
Study 11122886 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pulse therapy with 13-cis-retinoic acid (13-cis-RA) after intensive chemoradiotherapy
Number of subjects: 0
Study 11122886 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-HPR (fenretinide)
Number of subjects: 0
Study 11122886 — intervention group
Group type: COMPARATOR
Intervention: ATRA (all-trans-retinoic acid)
Number of subjects: 0
Study 11122886 — intervention group
Group type: COMPARATOR
Intervention: 13-cis-retinoic acid (13-cis-RA)
Number of subjects: 0
Study 9056730 — intervention group
Group type: EXPERIMENTAL
Intervention: Dowdo (wheat-milk gruel)
Number of subjects: 76
Study 9056730 — intervention group
Group type: COMPARATOR
Intervention: Khitchri (rice-lentil mixture)
Number of subjects: 76
Study 8364131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (n = 46)
Number of subjects: 92
Study 8364131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 46)
Number of subjects: 92
Study 3794070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure tones (220, 1100, or 3850 Hz)
Number of subjects: 12
Study 3794070 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex tone (18-tone complex with components between 110 and 7260 Hz)
Number of subjects: 12
Study 3794070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure tones (experiment 2)
Number of subjects: 12
Study 3794070 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex tone (experiment 2)
Number of subjects: 12
Study 30919883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination
Number of subjects: 75
Study 30919883 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 75
Study 30919883 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG given with Tdap or after Tdap
Number of subjects: 75
Study 29657199 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese group (BMI <23 Kg/m2)
Number of subjects: 51
Study 29657199 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese group (BMI >23 Kg/m2)
Number of subjects: 51
Study 29657199 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 51
Study 26833209 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based care management delivered by medical assistants
Number of subjects: 2076
Study 22999393 — intervention group
Group type: EXPERIMENTAL
Intervention: KT (blood flow restriction with occlusion pressure of approximately 230mmHg)
Number of subjects: 30
Study 22999393 — intervention group
Group type: EXPERIMENTAL
Intervention: HT (normobaric hypoxic exposure with blood oxyhaemoglobin levels of approximately 80%)
Number of subjects: 30
Study 22999393 — intervention group
Group type: COMPARATOR
Intervention: CT (no additional stimulus)
Number of subjects: 30
Study 21091926 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimates of gestational age using women's report of last menstrual period and physical examination
Number of subjects: 4484
Study 21091926 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound for determining eligibility
Number of subjects: 4484
Study 18431947 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity level; perceived benefits of physical activity; self-efficacy for leisure time physical activity; perceived school climate for girls' physical activity influenced by teachers
Number of subjects: 1511
Study 18431947 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 1511
Study 18431947 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/Ethnicity (Blacks vs. Whites)
Number of subjects: 1511
Study 18431947 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy; perceived benefits; race/ethnicity; teachers' support for girls' physical activity
Number of subjects: 1511
Study 18431947 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall model
Number of subjects: 1511
Study 17173588 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser plus topical 5-flurouracil
Number of subjects: 9
Study 17173588 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what treatment)
Number of subjects: 9
Study 12686924 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal flap
Number of subjects: 27
Study 12686924 — intervention group
Group type: COMPARATOR
Intervention: Paramarginal flap
Number of subjects: 27
Study 11168236 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ implants
Number of subjects: 61
Study 11168236 — intervention group
Group type: COMPARATOR
Intervention: Brånemark implants
Number of subjects: 61
Study 11168236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IMZ and Brånemark implants
Number of subjects: 61
Study 9114824 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b
Number of subjects: 0
Study 9114824 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a
Number of subjects: 0
Study 9114824 — intervention group
Group type: EXPERIMENTAL
Intervention: Copolymer 1
Number of subjects: 0
Study 9114824 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and corticotropin
Number of subjects: 0
Study 9114824 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein growth factors
Number of subjects: 0
Study 9114824 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐aminopyridine and 3,4‐diaminopyridine
Number of subjects: 0
Study 9114824 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental agents (other interferons, methotrexate, linomide, monoclonal antibodies, T‐cell receptor peptides, 2‐chlorodeoxyadenosine)
Number of subjects: 0
Study 8315363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8315363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological interventions
Number of subjects: 0
Study 3812669 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting with a 750-kcal mixed meal (14% protein, 31% fat, 55% carbohydrate)
Number of subjects: 16
Study 3812669 — intervention group
Group type: COMPARATOR
Intervention: Resting with no meal
Number of subjects: 16
Study 3812669 — intervention group
Group type: COMPARATOR
Intervention: 30 min of cycling with no meal
Number of subjects: 16
Study 3812669 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of cycling, meal 30 min before exercise
Number of subjects: 16
Study 3812669 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of cycling, meal immediately after exercise
Number of subjects: 16
Study 29223182 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading life stories (n = 19)
Number of subjects: 40
Study 29223182 — intervention group
Group type: COMPARATOR
Intervention: Reading file notes (n = 21)
Number of subjects: 40
Study 26589483 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Adduction exercise (CA) - 8-week supervised progressive training program
Number of subjects: 24
Study 26589483 — intervention group
Group type: COMPARATOR
Intervention: Control group - continued training as usual
Number of subjects: 24
Study 23452940 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-supported comprehensive lifestyle intervention programme (CLIP: written structured diet and exercise advice, plus seven telephone sessions with the Heart Foundation Health Information Service)
Number of subjects: 49
Study 23452940 — intervention group
Group type: COMPARATOR
Intervention: Usual care from their general practitioner (control: written general lifestyle advice)
Number of subjects: 49
Study 23452940 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIP
Number of subjects: 49
Study 22858215 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation program alone
Number of subjects: 407
Study 22858215 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation program plus online peer support
Number of subjects: 407
Study 22858215 — intervention group
Group type: COMPARATOR
Intervention: Attentional control condition
Number of subjects: 407
Study 20493480 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic dilation with an achalasia balloon
Number of subjects: 39
Study 20493480 — intervention group
Group type: COMPARATOR
Intervention: Surgical removal of the ring
Number of subjects: 39
Study 18221251 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (40 g, 12% solution)
Number of subjects: 50
Study 18221251 — intervention group
Group type: COMPARATOR
Intervention: High fructose corn syrup (HFCS)
Number of subjects: 50
Study 20877359 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with CA 19-9 monitoring
Number of subjects: 0
Study 16215338 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 107
Study 16215338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 12140392 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium (50 mg)
Number of subjects: 12
Study 12140392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 12
Study 9935257 — intervention group
Group type: EXPERIMENTAL
Intervention: Alatrofloxacin (200 mg intravenous)
Number of subjects: 492
Study 9935257 — intervention group
Group type: COMPARATOR
Intervention: Cefotetan (2 g intravenous)
Number of subjects: 492
Study 8148278 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 0.1 g twice daily
Number of subjects: 15
Study 8148278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline 0.6 g twice daily
Number of subjects: 15
Study 8148278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3130927 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate 500 mg weekly with proguanil hydrochloride 200 mg daily
Number of subjects: 767
Study 3130927 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 500 mg weekly with sulfadoxine 500 mg‐pyrimethamine 25 mg weekly
Number of subjects: 767
Study 3130927 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate with proguanil hydrochloride
Number of subjects: 767
Study 3130927 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine with sulfadoxine‐pyrimethamine
Number of subjects: 767
Study 27121082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal measure of hunger (squeezing a dynamometer)
Number of subjects: 106
Study 27121082 — intervention group
Group type: COMPARATOR
Intervention: Verbal measure of hunger (traditional self-report rating scale)
Number of subjects: 106
Study 27121082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal measure of hunger followed by verbal measure
Number of subjects: 106
Study 27121082 — intervention group
Group type: EXPERIMENTAL
Intervention: Only nonverbal measure of hunger
Number of subjects: 106
Study 27737714 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)
Number of subjects: 60
Study 27737714 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 60
Study 24633823 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel plus bivalirudin
Number of subjects: 0
Study 24633823 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus unfractionated heparin
Number of subjects: 0
Study 22494826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation (100,000 IU every 3 months for 18 months)
Number of subjects: 3046
Study 22494826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3046
Study 20975054 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release melatonin (Circadin®) at a dose of 2 mg 1 hour before bedtime for 8 weeks
Number of subjects: 48
Study 20975054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19006470 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of omega-3-acid ethyl esters (P-OM3) with 80 mg atorvastatin daily
Number of subjects: 50
Study 19006470 — intervention group
Group type: COMPARATOR
Intervention: 80 mg atorvastatin daily
Number of subjects: 50
Study 16049685 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy-tonsillectomy
Number of subjects: 400
Study 16049685 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy alone
Number of subjects: 400
Study 16049685 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy alone
Number of subjects: 400
Study 16049685 — intervention group
Group type: COMPARATOR
Intervention: Routine histological examination
Number of subjects: 400
Study 12548212 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (20 microg every 2 hours, increased to 40 microg depending on uterine contractions)
Number of subjects: 200
Study 12548212 — intervention group
Group type: COMPARATOR
Intervention: Vaginal dinoprostone (2 mg twice, 6 hours apart)
Number of subjects: 200
Study 10373048 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor test (10 min duration)
Number of subjects: 80
Study 10373048 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor test
Number of subjects: 80
Study 10373048 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinical examination)
Number of subjects: 80
Study 8561069 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (2.5 g/d for 2 months)
Number of subjects: 12
Study 1652597 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogen and progestin (conjugated equine estrogens, 2.5 mg/day and medroxyprogesterone acetate, 60 mg/day)
Number of subjects: 12
Study 1652597 — intervention group
Group type: COMPARATOR
Intervention: Estrogen (conjugated equine estrogens, 2.5 mg/day)
Number of subjects: 12
Study 1652597 — intervention group
Group type: COMPARATOR
Intervention: Progestin (medroxyprogesterone acetate, 60 mg/day)
Number of subjects: 12
Study 1652597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7039527 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin prophylaxis
Number of subjects: 92
Study 7039527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 29360046 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented prescriptive knowledge of performance feedback (PKP)
Number of subjects: 31
Study 29360046 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of results feedback only (Control)
Number of subjects: 31
Study 28002472 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program (WSTP)
Number of subjects: 106
Study 28002472 — intervention group
Group type: COMPARATOR
Intervention: Educational Control (EC)
Number of subjects: 106
Study 23556467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss(®) Collagen (graft material not included)
Number of subjects: 25
Study 23556467 — intervention group
Group type: COMPARATOR
Intervention: Control (no grafting performed)
Number of subjects: 25
Study 23556467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss(®) Collagen (graft material included)
Number of subjects: 25
Study 22922768 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncho‐Vaxom (7 mg daily for the first 10 days of each month for 3 months)
Number of subjects: 40